The role of dipyridamole in addition to low dose aspirin in the prevention of occlusion of coronary artery bypass grafts.

T. M. Agnew, J. K. French, J. M. Neutze, R. M. Whitlock, P. W. Brandt, A. R. Kerr, B. J. Webber, J. D. Rutherford

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

One hundred and one subjects were randomised to receive either aspirin 100 mg or aspirin 100 mg + dipyridamole 300 mg daily before undergoing coronary bypass surgery. The drugs were commenced at least 36 hours before operation and patients were followed for one year. There were three perioperative deaths and 37 withdrawals, of which 14 were drug related (aspirin four, aspirin + dipyridamole ten). Cineangiocardiograms at nine weeks and one year showed vein graft patency rates of 93% and 87% for subjects treated with aspirin alone; and 90% and 89% in those who received aspirin+dipyridamole. During the follow-up period 14% of 232 coronary lesions in the aspirin treated group advanced by more than two grades compared with 15% of 315 lesions in the aspirin+dipyridamole group. The study did not establish superiority of one regimen over another in terms of graft patency or progress of lesions in native vessels. However, low dose aspirin was better tolerated than combination therapy.

Original languageEnglish (US)
Pages (from-to)665-670
Number of pages6
JournalAustralian and New Zealand Journal of Medicine
Volume22
Issue number6
StatePublished - Dec 1992

Fingerprint

Dipyridamole
Coronary Artery Bypass
Aspirin
Transplants
Pharmaceutical Preparations
Veins

ASJC Scopus subject areas

  • Internal Medicine

Cite this

The role of dipyridamole in addition to low dose aspirin in the prevention of occlusion of coronary artery bypass grafts. / Agnew, T. M.; French, J. K.; Neutze, J. M.; Whitlock, R. M.; Brandt, P. W.; Kerr, A. R.; Webber, B. J.; Rutherford, J. D.

In: Australian and New Zealand Journal of Medicine, Vol. 22, No. 6, 12.1992, p. 665-670.

Research output: Contribution to journalArticle

Agnew, T. M. ; French, J. K. ; Neutze, J. M. ; Whitlock, R. M. ; Brandt, P. W. ; Kerr, A. R. ; Webber, B. J. ; Rutherford, J. D. / The role of dipyridamole in addition to low dose aspirin in the prevention of occlusion of coronary artery bypass grafts. In: Australian and New Zealand Journal of Medicine. 1992 ; Vol. 22, No. 6. pp. 665-670.
@article{92d519bd1b744f10b0b6aa8e87a390c6,
title = "The role of dipyridamole in addition to low dose aspirin in the prevention of occlusion of coronary artery bypass grafts.",
abstract = "One hundred and one subjects were randomised to receive either aspirin 100 mg or aspirin 100 mg + dipyridamole 300 mg daily before undergoing coronary bypass surgery. The drugs were commenced at least 36 hours before operation and patients were followed for one year. There were three perioperative deaths and 37 withdrawals, of which 14 were drug related (aspirin four, aspirin + dipyridamole ten). Cineangiocardiograms at nine weeks and one year showed vein graft patency rates of 93{\%} and 87{\%} for subjects treated with aspirin alone; and 90{\%} and 89{\%} in those who received aspirin+dipyridamole. During the follow-up period 14{\%} of 232 coronary lesions in the aspirin treated group advanced by more than two grades compared with 15{\%} of 315 lesions in the aspirin+dipyridamole group. The study did not establish superiority of one regimen over another in terms of graft patency or progress of lesions in native vessels. However, low dose aspirin was better tolerated than combination therapy.",
author = "Agnew, {T. M.} and French, {J. K.} and Neutze, {J. M.} and Whitlock, {R. M.} and Brandt, {P. W.} and Kerr, {A. R.} and Webber, {B. J.} and Rutherford, {J. D.}",
year = "1992",
month = "12",
language = "English (US)",
volume = "22",
pages = "665--670",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The role of dipyridamole in addition to low dose aspirin in the prevention of occlusion of coronary artery bypass grafts.

AU - Agnew, T. M.

AU - French, J. K.

AU - Neutze, J. M.

AU - Whitlock, R. M.

AU - Brandt, P. W.

AU - Kerr, A. R.

AU - Webber, B. J.

AU - Rutherford, J. D.

PY - 1992/12

Y1 - 1992/12

N2 - One hundred and one subjects were randomised to receive either aspirin 100 mg or aspirin 100 mg + dipyridamole 300 mg daily before undergoing coronary bypass surgery. The drugs were commenced at least 36 hours before operation and patients were followed for one year. There were three perioperative deaths and 37 withdrawals, of which 14 were drug related (aspirin four, aspirin + dipyridamole ten). Cineangiocardiograms at nine weeks and one year showed vein graft patency rates of 93% and 87% for subjects treated with aspirin alone; and 90% and 89% in those who received aspirin+dipyridamole. During the follow-up period 14% of 232 coronary lesions in the aspirin treated group advanced by more than two grades compared with 15% of 315 lesions in the aspirin+dipyridamole group. The study did not establish superiority of one regimen over another in terms of graft patency or progress of lesions in native vessels. However, low dose aspirin was better tolerated than combination therapy.

AB - One hundred and one subjects were randomised to receive either aspirin 100 mg or aspirin 100 mg + dipyridamole 300 mg daily before undergoing coronary bypass surgery. The drugs were commenced at least 36 hours before operation and patients were followed for one year. There were three perioperative deaths and 37 withdrawals, of which 14 were drug related (aspirin four, aspirin + dipyridamole ten). Cineangiocardiograms at nine weeks and one year showed vein graft patency rates of 93% and 87% for subjects treated with aspirin alone; and 90% and 89% in those who received aspirin+dipyridamole. During the follow-up period 14% of 232 coronary lesions in the aspirin treated group advanced by more than two grades compared with 15% of 315 lesions in the aspirin+dipyridamole group. The study did not establish superiority of one regimen over another in terms of graft patency or progress of lesions in native vessels. However, low dose aspirin was better tolerated than combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=0027032056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027032056&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 665

EP - 670

JO - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

IS - 6

ER -